Last Updated: November 16, 2026

Drug Sales Trends for NOVOLIN N

« Back to Dashboard


Drug Sales Revenue Trends for NOVOLIN N
Drug Units Sold Trends for NOVOLIN N

Annual Sales Revenues and Units Sold for NOVOLIN N

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
NOVOLIN N ⤷  Start Trial ⤷  Start Trial 2022
NOVOLIN N ⤷  Start Trial ⤷  Start Trial 2021
NOVOLIN N ⤷  Start Trial ⤷  Start Trial 2020
NOVOLIN N ⤷  Start Trial ⤷  Start Trial 2019
NOVOLIN N ⤷  Start Trial ⤷  Start Trial 2018
NOVOLIN N ⤷  Start Trial ⤷  Start Trial 2017
>Drug Name >Revenues (USD) >Units >Year

Novolin N Market Analysis, Sales Forecast, Patent Position, and Competitive Outlook

Last updated: September 1, 2026

Novolin N is a mature human NPH insulin marketed by Novo Nordisk for basal glycemic control. Its commercial position is supported by low acquisition cost, broad physician familiarity, and access through cash-pay and over-the-counter channels in parts of the U.S. The product faces structural decline from insulin analogs, including insulin glargine and insulin degludec, but retains demand among price-sensitive patients, public payers, and markets where analog insulin remains unaffordable.

Novo Nordisk does not report Novolin N revenue as a standalone product. The forecast below therefore uses an indexed model rather than an unsupported dollar estimate. The base case assumes a 2% to 3% annual unit decline through 2030, partially offset by price stability and continued demand in low-cost channels.

What is Novolin N and how is it used?

Novolin N contains insulin isophane human, also called NPH insulin. It is an intermediate-acting insulin suspension administered subcutaneously for the treatment of diabetes mellitus. Its duration is generally about 12 to 18 hours, although absorption varies materially among patients.

Product attribute Novolin N profile
Active ingredient Insulin isophane human, NPH
Manufacturer Novo Nordisk
Dosage forms 10 mL vial and FlexPen presentations in selected markets
Primary use Intermediate-acting basal insulin
Typical dosing Once or twice daily, individualized
Main U.S. competitors Humulin N, ReliOn Novolin N, insulin analogs
Principal safety issue Hypoglycemia, including nocturnal hypoglycemia
FDA status FDA-approved human insulin product
Prescription status Availability varies by state and channel
Commercial position Mature, low-cost insulin product

Novolin N is commonly used alone, with short-acting insulin, or in combination regimens. It is also sold in premixed products such as Novolin 70/30, although the premixed product has a separate commercial profile.

What is the market size for Novolin N and NPH insulin?

The addressable market has two distinct segments:

  1. The global intermediate-acting human insulin market, which includes NPH products.
  2. The broader basal insulin market, where NPH competes with insulin glargine, insulin detemir, insulin degludec, and biosimilar or follow-on products.

Novolin N’s strongest commercial markets are the United States, Latin America, parts of Asia, and lower-income markets where NPH remains available through public procurement. In wealthier markets, basal insulin analogs have replaced a large proportion of NPH use because of lower nocturnal hypoglycemia risk, more predictable pharmacokinetics, and simpler dosing.

Novo Nordisk reports insulin sales within broader diabetes-care categories. It does not separately disclose revenue for Novolin N, making product-level market-share and sales calculations unavailable from public company filings. [1]

Market drivers

Driver Effect on Novolin N
Low acquisition cost Positive
Public-sector insulin tenders Positive
OTC and cash-pay access Positive in the U.S.
Shift to insulin analogs Negative
Greater use of continuous glucose monitoring Mixed
Diabetes prevalence growth Positive
Hypoglycemia concerns Negative
Insulin affordability pressure Positive for NPH demand
Biosimilar insulin competition Indirectly negative

The main demand support is affordability. The American Diabetes Association and other clinical groups generally recognize NPH as a lower-cost alternative, although treatment selection depends on hypoglycemia risk, patient adherence, dosing schedule, and payer coverage. [2]

What are the Novolin N sales projections through 2030?

Because Novo Nordisk does not disclose Novolin N revenue, the following forecast uses 2024 sales as an indexed base of 100.

Scenario 2030 revenue index Implied annual trend Principal assumptions
Downside 72 Approximately -5.1% Faster conversion to analogs, lower public-tender volumes, loss of cash-pay share
Base case 86 Approximately -2.5% Gradual unit decline, stable low-cost demand, limited price increases
Upside 108 Approximately +1.3% Expanded affordability programs, stronger emerging-market demand, supply continuity

Base-case forecast

Year Revenue index Market interpretation
2024 100 Reference year
2025 98 Mature-product erosion continues
2026 95 Analog substitution remains gradual
2027 93 Low-cost demand offsets part of unit decline
2028 91 Public-sector and cash-pay channels remain important
2029 88 Competitive pressure increases
2030 86 Product remains commercially relevant but structurally declining

The most likely outcome is declining revenue with continued positive cash generation. Novolin N does not require the same level of clinical differentiation or promotional investment as newer basal insulins. Its strategic value is its position in the low-cost segment, rather than rapid growth.

For every $100 million of 2024 Novolin N revenue, the base case produces approximately $86 million in 2030 revenue. The downside case produces $72 million, while the upside case produces $108 million.

What is the U.S. pricing and access position for Novolin N?

Novolin N has a two-tiered U.S. commercial model:

  • Insured prescriptions distributed through pharmacies and benefit managers.
  • Cash-pay purchases, including lower-cost retail channels such as Walmart’s ReliOn program.

Walmart markets ReliOn Novolin products at substantially lower cash prices than many branded insulin analogs. Retail prices vary by vial, pen, state, pharmacy, and supply conditions. The low-price channel limits Novolin N’s gross-to-net expansion but improves volume retention among uninsured and underinsured patients. [3]

The product’s affordability advantage is most significant for patients who pay cash or face high deductibles. For insured patients, formulary rebates can make analog insulin financially competitive with NPH, reducing the benefit of Novolin N’s list-price position.

U.S. reimbursement risks

Novolin N is exposed to:

  • Formulary exclusion in favor of preferred analog insulin.
  • Pharmacy benefit manager reimbursement changes.
  • State-level restrictions on nonprescription insulin sales.
  • Patient switching caused by deductible resets.
  • Supply disruptions that push patients toward competing human insulin.

Medicare Part D reforms and the federal insulin cost-sharing cap improve affordability for eligible beneficiaries, but they can also reduce the relative advantage of a low-list-price product. [4]

How does Novolin N compare with Humulin N and insulin analogs?

Novolin N versus Humulin N

Novolin N and Humulin N are direct human-insulin competitors. Both are NPH products with similar clinical roles and comparable safety limitations. The competition is mainly commercial:

Factor Novolin N Humulin N
Manufacturer Novo Nordisk Eli Lilly
Insulin type Human NPH Human NPH
Clinical role Intermediate-acting basal insulin Intermediate-acting basal insulin
Key advantage Retail and global distribution Established Lilly supply base
Key risk Analog substitution Analog substitution
Differentiation Limited Limited

Price, availability, payer contracts, and physician familiarity are more important than clinical differentiation.

Novolin N versus insulin glargine

Insulin glargine products, including Lantus, Basaglar, Semglee, and Rezvoglar, generally offer once-daily dosing and a flatter action profile than NPH. NPH remains less expensive in many cash-pay settings, but glargine has a stronger position in patients at risk of nocturnal hypoglycemia or those needing a simpler regimen.

Novolin N versus insulin degludec

Tresiba, or insulin degludec, has a substantially longer duration and greater dosing flexibility. Its price is typically higher, which limits use in cost-sensitive markets. Degludec is a commercial substitute for Novolin N in premium and specialist-driven segments, not a direct low-cost replacement in every geography.

What patents protect Novolin N, and when does it lose exclusivity?

Novolin N is a mature human insulin product. Its core composition and basic formulation protections are not meaningful barriers to competition in 2025. The product’s commercial protection comes primarily from manufacturing know-how, regulatory approvals, distribution, supply reliability, and brand recognition.

IP category Current relevance
Core NPH insulin composition Mature technology; no meaningful new-product exclusivity
Basic suspension formulation Mature and readily replicated by established insulin manufacturers
Delivery-device patents May apply to specific pens or components, not the active ingredient
Manufacturing know-how High practical relevance
Trademark protection Protects NOVOLIN branding, not competing NPH insulin
Method-of-use patents Limited relevance for a decades-old human insulin product
Orange Book patent exclusivity No commercially significant remaining core-patent barrier identified

The absence of a strong patent barrier does not mean immediate generic substitution. Insulin manufacturing requires validated cell-culture or recombinant production, purification, formulation, sterile filling, device compatibility, stability testing, and regulatory comparability. These requirements create operational barriers even when composition patents have expired.

What is the FDA regulatory and Orange Book status of Novolin N?

Novolin N is an FDA-approved human insulin product. Its regulatory position is distinct from small-molecule generics because insulin is a biologic product and follow-on products require a regulatory pathway that addresses biological similarity and manufacturing consistency.

The FDA transitioned insulin products to the biologics framework in 2020. This transition created a clearer pathway for biosimilar and interchangeable insulin products, although it did not eliminate the manufacturing and clinical risks associated with insulin development. [5]

Novolin N itself is not a newly launched biologic with a long remaining exclusivity period. Its commercial exposure is therefore not driven by FDA exclusivity. The primary regulatory risks are:

  • Manufacturing deviations.
  • Product recalls.
  • Labeling or device changes.
  • Supply interruptions.
  • State-level restrictions on nonprescription sale.
  • Product substitution by other approved insulins.

Which companies are challenging Novolin N?

The main competitive threats are commercial rather than litigation-based.

Competitor Company Competitive effect
Humulin N Eli Lilly Direct NPH substitution
ReliOn Novolin N Walmart/Novo Nordisk retail channel Expands low-price distribution
Semglee Viatris/Biocon Lowers the cost of insulin glargine
Rezvoglar Eli Lilly Adds lower-cost glargine competition
Basaglar Eli Lilly Competes in basal insulin
Lantus Sanofi Established analog brand
Tresiba Novo Nordisk Internal substitution toward premium basal insulin

No major Paragraph IV challenge is central to Novolin N’s current commercial outlook. Paragraph IV litigation is generally associated with patent-protected products facing abbreviated new drug applications. Novolin N is a mature insulin product, and its key commercial risks do not depend on unresolved core patents.

What manufacturing and intellectual-property barriers affect Novolin N?

Manufacturing is the strongest practical barrier to entry. A competitor must establish:

  • Recombinant human insulin production.
  • Consistent protamine-zinc suspension characteristics.
  • Sterile filling and container-closure integrity.
  • Stability across temperature and transport conditions.
  • Reliable vial and pen-device performance.
  • Batch-to-batch potency and impurity control.
  • Regulatory comparability and interchangeability data where applicable.

Novo Nordisk’s scale and insulin manufacturing infrastructure support supply reliability and tender participation. Those advantages are more defensible than the underlying chemical or biological composition.

The principal manufacturing risks are concentrated production, raw-material constraints, device-component shortages, and regulatory inspection findings. A supply disruption could temporarily transfer share to Humulin N or other basal insulins.

What litigation and settlement issues affect Novolin N?

No major current patent litigation or settlement agreement is known to be driving Novolin N’s market position. The absence of a litigation-driven launch date is commercially important. Novolin N’s forecast is governed by substitution, pricing, supply, and payer decisions rather than a single patent-loss event.

Litigation risk could still arise from:

  • Manufacturing or product-liability claims.
  • Device-related disputes involving FlexPen products.
  • Pricing or rebate investigations affecting insulin distribution.
  • Patent disputes involving competing insulin analogs that alter formulary access.

These risks are secondary to the product’s mature-market decline.

What geographic markets offer the strongest Novolin N opportunity?

Novolin N has its strongest relative opportunity where insulin affordability constrains analog adoption.

Geography Outlook
United States Stable niche; strong cash-pay relevance but persistent analog substitution
Latin America Positive volume potential through public procurement and lower-cost regimens
Asia Mixed; large diabetes population but intense local and multinational competition
Europe Declining share in mature markets; reimbursement and tender pricing dominate
Middle East and Africa Potentially attractive where NPH remains a standard low-cost insulin
Low-income public-health markets Volume opportunity, but low margins and tender pressure

The commercial model differs by geography. U.S. sales rely on pharmacy access, cash-pay pricing, and reimbursement. Emerging-market sales rely more heavily on government tenders, distributor coverage, and supply continuity.

What generic launch risks exist for Novolin N?

The risk of a classic generic launch is limited because insulin is regulated as a biologic rather than as a conventional small-molecule drug. The more relevant threat is follow-on insulin competition.

Near-term risk

The near-term risk is moderate. Humulin N is already a direct competitor, and low-cost insulin analogs are expanding. However, many patients and health systems continue to use NPH because of price and clinical familiarity.

Medium-term risk

The medium-term risk is moderate to high. Greater availability of biosimilar or interchangeable basal analogs can narrow the price gap between NPH and analog insulin. If glargine prices fall materially, Novolin N may lose patients who currently use it for affordability.

Launch scenario

Scenario Likely commercial effect
No major new competitor Gradual annual decline
Low-cost glargine expansion Faster conversion among insured patients
NPH price reduction Volume stabilization but lower revenue per unit
Supply disruption Temporary share loss and reputational damage
Public-tender expansion Volume growth with margin compression

How strong is the Novolin N commercial estate?

Novolin N has a weak patent estate but a durable operating position.

Dimension Assessment
Core patent protection Weak
Regulatory exclusivity Minimal
Manufacturing barrier Moderate to high
Brand recognition High
Price competitiveness High
Clinical differentiation Low
Distribution reach High
Exposure to analog substitution High
Litigation protection Low relevance
Long-term growth potential Low
Cash-generation potential Moderate

The product’s value is defensive. It can preserve volume in low-cost insulin markets and support portfolio coverage, but it is unlikely to be a major growth engine for Novo Nordisk.

Key Takeaways

  • Novolin N is a mature NPH insulin with limited remaining patent-based protection.
  • Novo Nordisk does not separately report Novolin N revenue, so product-level dollar forecasts require modeling.
  • The base-case forecast indicates an indexed revenue decline from 100 in 2024 to approximately 86 in 2030.
  • Low cash prices, public tenders, and emerging-market demand support continued use.
  • Insulin glargine, insulin degludec, and lower-cost follow-on insulins are the principal competitive threats.
  • No major Paragraph IV event or patent settlement currently determines Novolin N’s market outlook.
  • Manufacturing capability, regulatory compliance, distribution, and supply reliability are more important than patent exclusivity.
  • The product has durable niche value but limited growth potential.

FAQs About Novolin N Market Outlook

Is Novolin N still commercially important?

Yes. Novolin N remains important in price-sensitive markets and among uninsured or underinsured U.S. patients, although its share of the broader basal-insulin market is declining.

Can Novolin N be replaced by insulin glargine?

Insulin glargine can replace NPH in many treatment regimens, but conversion requires clinician-directed dose adjustment and monitoring because the products have different pharmacokinetic and hypoglycemia profiles.

Does Novolin N have biosimilar competition?

Novolin N faces competition from other human NPH insulin products and indirect competition from biosimilar or follow-on basal analogs. The competitive impact depends on regulatory approval, interchangeability, price, and payer placement.

Is ReliOn Novolin N a separate insulin product?

ReliOn Novolin N is generally a lower-cost retail-branded presentation supplied through the Walmart channel. The commercial distinction is branding and distribution rather than a different insulin mechanism.

Will Novolin N sales grow in emerging markets?

Volume may grow in selected emerging markets, but tender pricing and low unit economics are likely to limit revenue growth. The strongest opportunity is market retention rather than premium pricing.

References

  1. Novo Nordisk A/S. (2025). Annual report 2024. Novo Nordisk.
  2. American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes: 2025. Diabetes Care, 48(Supplement 1).
  3. Walmart. (2025). ReliOn Novolin insulin product listings. Walmart Pharmacy.
  4. Centers for Medicare & Medicaid Services. (2024). Medicare insulin cost-sharing provisions. U.S. Department of Health and Human Services.
  5. U.S. Food and Drug Administration. (2020). Insulin products regulated under the Public Health Service Act. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.